Eosinophilic esophagitis: latest insights from diagnosis to therapy

Alain Schoepfer, Carine Blanchard, Heather Dawson, Alfredo Lucendo, Aurelio Mauro, Camillo Ribi, Ekaterina Safroneeva, Edoardo V. Savarino, Roberto Penagini

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Eosinophilic esophagitis (EoE) represents a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Other systemic and local causes of esophageal eosinophilia should be excluded. Clinical manifestations or pathologic data should not be interpreted in isolation. EoE was first described as a distinct disease entity in 1993. Most patients are diagnosed with underlying food allergies. The first diagnostic and therapeutic guidelines were published in 2007 with a first update in 2011. In 2017, new international guidelines were published based on the GRADE methodology. These guidelines provide, among many other topics, insights on the role of proton pump inhibitor-responsive esophageal eosinophilia. Over the last two decades, considerable progress was made by stakeholders regarding the understanding of EoE's pathogenesis, genetic background, natural history, allergy workup, standardization of assessment of disease activity, evaluation of minimally invasive diagnostic tools, and new therapeutic approaches. This brief review provides further insights into latest diagnostic and therapeutic advances.

Original languageEnglish
Pages (from-to)84-93
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume1434
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Eosinophilic Esophagitis
Delayed Diagnosis
Allergies
Eosinophilia
Guidelines
Esophageal Diseases
Food Hypersensitivity
Proton Pump Inhibitors
Natural History
Eosinophils
Standardization
Hypersensitivity
Therapeutics
Inflammation
Diagnostics
Therapy
Allergy

Keywords

  • dysphagia
  • eosinophilic esophagitis
  • food allergy
  • guidelines
  • patient-reported outcomes
  • proton pump inhibitor-responsive esophageal eosinophilia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Eosinophilic esophagitis : latest insights from diagnosis to therapy. / Schoepfer, Alain; Blanchard, Carine; Dawson, Heather; Lucendo, Alfredo; Mauro, Aurelio; Ribi, Camillo; Safroneeva, Ekaterina; Savarino, Edoardo V.; Penagini, Roberto.

In: Annals of the New York Academy of Sciences, Vol. 1434, No. 1, 01.12.2018, p. 84-93.

Research output: Contribution to journalReview article

Schoepfer, A, Blanchard, C, Dawson, H, Lucendo, A, Mauro, A, Ribi, C, Safroneeva, E, Savarino, EV & Penagini, R 2018, 'Eosinophilic esophagitis: latest insights from diagnosis to therapy', Annals of the New York Academy of Sciences, vol. 1434, no. 1, pp. 84-93. https://doi.org/10.1111/nyas.13731
Schoepfer, Alain ; Blanchard, Carine ; Dawson, Heather ; Lucendo, Alfredo ; Mauro, Aurelio ; Ribi, Camillo ; Safroneeva, Ekaterina ; Savarino, Edoardo V. ; Penagini, Roberto. / Eosinophilic esophagitis : latest insights from diagnosis to therapy. In: Annals of the New York Academy of Sciences. 2018 ; Vol. 1434, No. 1. pp. 84-93.
@article{418cfcc6969d4f0d89e36fe429e364f2,
title = "Eosinophilic esophagitis: latest insights from diagnosis to therapy",
abstract = "Eosinophilic esophagitis (EoE) represents a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Other systemic and local causes of esophageal eosinophilia should be excluded. Clinical manifestations or pathologic data should not be interpreted in isolation. EoE was first described as a distinct disease entity in 1993. Most patients are diagnosed with underlying food allergies. The first diagnostic and therapeutic guidelines were published in 2007 with a first update in 2011. In 2017, new international guidelines were published based on the GRADE methodology. These guidelines provide, among many other topics, insights on the role of proton pump inhibitor-responsive esophageal eosinophilia. Over the last two decades, considerable progress was made by stakeholders regarding the understanding of EoE's pathogenesis, genetic background, natural history, allergy workup, standardization of assessment of disease activity, evaluation of minimally invasive diagnostic tools, and new therapeutic approaches. This brief review provides further insights into latest diagnostic and therapeutic advances.",
keywords = "dysphagia, eosinophilic esophagitis, food allergy, guidelines, patient-reported outcomes, proton pump inhibitor-responsive esophageal eosinophilia",
author = "Alain Schoepfer and Carine Blanchard and Heather Dawson and Alfredo Lucendo and Aurelio Mauro and Camillo Ribi and Ekaterina Safroneeva and Savarino, {Edoardo V.} and Roberto Penagini",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/nyas.13731",
language = "English",
volume = "1434",
pages = "84--93",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Eosinophilic esophagitis

T2 - latest insights from diagnosis to therapy

AU - Schoepfer, Alain

AU - Blanchard, Carine

AU - Dawson, Heather

AU - Lucendo, Alfredo

AU - Mauro, Aurelio

AU - Ribi, Camillo

AU - Safroneeva, Ekaterina

AU - Savarino, Edoardo V.

AU - Penagini, Roberto

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Eosinophilic esophagitis (EoE) represents a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Other systemic and local causes of esophageal eosinophilia should be excluded. Clinical manifestations or pathologic data should not be interpreted in isolation. EoE was first described as a distinct disease entity in 1993. Most patients are diagnosed with underlying food allergies. The first diagnostic and therapeutic guidelines were published in 2007 with a first update in 2011. In 2017, new international guidelines were published based on the GRADE methodology. These guidelines provide, among many other topics, insights on the role of proton pump inhibitor-responsive esophageal eosinophilia. Over the last two decades, considerable progress was made by stakeholders regarding the understanding of EoE's pathogenesis, genetic background, natural history, allergy workup, standardization of assessment of disease activity, evaluation of minimally invasive diagnostic tools, and new therapeutic approaches. This brief review provides further insights into latest diagnostic and therapeutic advances.

AB - Eosinophilic esophagitis (EoE) represents a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Other systemic and local causes of esophageal eosinophilia should be excluded. Clinical manifestations or pathologic data should not be interpreted in isolation. EoE was first described as a distinct disease entity in 1993. Most patients are diagnosed with underlying food allergies. The first diagnostic and therapeutic guidelines were published in 2007 with a first update in 2011. In 2017, new international guidelines were published based on the GRADE methodology. These guidelines provide, among many other topics, insights on the role of proton pump inhibitor-responsive esophageal eosinophilia. Over the last two decades, considerable progress was made by stakeholders regarding the understanding of EoE's pathogenesis, genetic background, natural history, allergy workup, standardization of assessment of disease activity, evaluation of minimally invasive diagnostic tools, and new therapeutic approaches. This brief review provides further insights into latest diagnostic and therapeutic advances.

KW - dysphagia

KW - eosinophilic esophagitis

KW - food allergy

KW - guidelines

KW - patient-reported outcomes

KW - proton pump inhibitor-responsive esophageal eosinophilia

UR - http://www.scopus.com/inward/record.url?scp=85053669408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053669408&partnerID=8YFLogxK

U2 - 10.1111/nyas.13731

DO - 10.1111/nyas.13731

M3 - Review article

C2 - 29762879

AN - SCOPUS:85053669408

VL - 1434

SP - 84

EP - 93

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -